CancerCANFRADENCT05350007
Evaluation of Rumination, Frailty and Tanatophobia in Cancer Patients Over 65 Years of Age
An observational study of Cancer and Death, run by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to evaluate tanatophobia and rumination in individuals over 65 years of age receiving cancer chemotherapy and to determine the related factors. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Cancer, Death, Rumination
- How many people
- 180 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 25 May 2022to 31 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Older adult
Study population: Cancer patients aged 65 and over receiving chemotherapy
Who may be able to join
- 65 years or older
- Conscious and no communication problems
- Being literate
- Willing to participate in our study voluntarily
- Cancer patient receiving active chemotherapy treatment
Who cannot join
- Not being willing to participate in the research
- Serious life-threatening condition (critical illness, intensive care unit stay, acute complication)
- Dementia, Alzheimer's, cognitive dysfunction
- Major psychiatric illness
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Sultan Abdülhamid Training and Research Hospital
Üsküdar, Istanbul, 34660
Elif Yıldırım Ayaz, M.D., 05325148300, drelifyildirim@hotmail.com
About this study
The aim of this study is to evaluate tanatophobia and rumination in individuals over 65 years of age receiving cancer chemotherapy and to determine the related factors.
Read the detailed description
No studies were found in the literature evaluating the relationship between frailty and lack of social support with tanatophobia and rumination. The aim of this study is to evaluate tanatophobia and rumination in individuals over 65 years of age receiving cancer chemotherapy and to determine the related factors.
- Conditions
- Cancer, Death, Rumination, Frailty
- Keywords
- cancer, tanatophobia, rumination, fraility, elderly
- Medical subject headings
- Neoplasms, Death, Rumination Syndrome, Frailty
What is being measured
The primary outcome is the main question the study is designed to answer.
Rumination
Evaluation of rumination in patients over 65 years of age receiving cancer chemotherapy
Measured: 1 week
Tanatophobia
Evaluation of tanatophobia in patients over 65 years of age receiving cancer chemotherapy
Measured: 1 week
Secondary outcomes (2)
fraility
Evaluation of fraility in patients over 65 years of age receiving cancer chemotherapy
Measured: 1 month
lack of social support
Evaluation of lack of social support in patients over 65 years of age receiving cancer chemotherapy
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2022
- Study start25 May 2022
- Primary completion31 Dec 2022 (estimated)
- Study completion31 Dec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elif Yıldırım Ayaz, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
- Investigators
- Elif Yıldırım Ayaz, M.D., Principal investigator, Sultan Abdülhamid Training And Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05350007
- Sponsor's protocol ID
- CANFRADE
- Acronym
- CANFRADE
- Status last verified
- Jun 2022
- First submitted
- 18 Apr 2022
- Last updated
- 22 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Rumination, Frailty and Tanatophobia in Cancer Patients Over 65 Years of Age
- ClinicalTrials.gov ID
- NCT05350007
- Acronym / sponsor ID
- CANFRADE / CANFRADE
- Conditions
- Cancer, Death, Rumination, Frailty
- Keywords
- cancer, tanatophobia, rumination, fraility, elderly
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyUniversity, hospital or other
- Study start
- 25 May 2022 (actual)
- Primary completion
- 31 Dec 2022 (estimated)
- Study completion
- 31 Dec 2022 (estimated)
- First posted
- 27 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate tanatophobia and rumination in individuals over 65 years of age receiving cancer chemotherapy and to determine the related factors.
Detailed description
No studies were found in the literature evaluating the relationship between frailty and lack of social support with tanatophobia and rumination. The aim of this study is to evaluate tanatophobia and rumination in individuals over 65 years of age receiving cancer chemotherapy and to determine the related factors.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Age groups
- Older adult
- Study population
- Cancer patients aged 65 and over receiving chemotherapy
Key inclusion criteria (5 listed)
- 65 years or older
- Conscious and no communication problems
- Being literate
- Willing to participate in our study voluntarily
- Cancer patient receiving active chemotherapy treatment
Key exclusion criteria (4 listed)
- Not being willing to participate in the research
- Serious life-threatening condition (critical illness, intensive care unit stay, acute complication)
- Dementia, Alzheimer's, cognitive dysfunction
- Major psychiatric illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Rumination
Time frame: 1 week
Evaluation of rumination in patients over 65 years of age receiving cancer chemotherapy
Tanatophobia
Time frame: 1 week
Evaluation of tanatophobia in patients over 65 years of age receiving cancer chemotherapy
2 secondary outcomes
fraility
Time frame: 1 month
lack of social support
Time frame: 1 month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elif Yıldırım Ayaz, M.D. principal investigator
Sultan Abdülhamid Training And Research Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Death, run by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Elif Yıldırım Ayaz, M.D. (+905325148300, drelifyildirim@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rumination (time frame: 1 week). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2022.